HK inno.N Eyes 2025 Korea Opportunity With mAbxience Denosumab Deal
Amgen’s Prolia/Xgeva Original Sales Close To $100m, mAbxience In Phase III
Executive Summary
Ahead of wrapping up a Phase III clinical trial for its proposed biosimilar denosumab candidate later this year, mAbxience has out-licensed marketing rights in Korea to local player HK inno.N, with a patent expiry opportunity in 2025.
You may also be interested in...
MGC And GlycoNex Kick Off Denosumab Trial In Japan
Mitsubishi Gas Chemical Company and GlycoNex have begun a Phase I trial in Japan for their SPD8 denosumab biosimilar. The partners are also “actively pursuing global development plans” for the rival to Prolia and Xgeva.
Sandoz Follows US Denosumab Filing With European Acceptance
Sandoz has confirmed dual European filings for its denosumab biosimilar rival to Prolia and Xgeva, a few months after it submitted its candidate in the US.
Deal Watch: BMS Returning IL-12 Candidate To Frequent Partner Dragonfly
The firms’ partnership goes back to pre-merger Celgene, and BMS still has Dragonfly candidates in its pipeline. Ji Xing gets hypertension candidate from Phase Bio.